NasdaqGS - Nasdaq Real Time Price USD

Sanofi (SNY)

45.39

-0.72

(-1.56%)

At close: April 18 at 4:00 PM EDT

46.00

+0.61

(+1.34%)

Pre-Market: 6:30 AM EDT

Sanofi to overhaul US operations of vaccines, cut jobs

Sanofi would implement a "streamlined strategic sales structure" to better support its customers and patients, it said without disclosing any details on the changes to be made, the timeframe and the number of employees to be impacted. Sanofi CEO Paul Hudson has been trying to build investor confidence in the company's drug pipeline since he unexpectedly abandoned 2025 margin targets last October to instead boost drug development spending. The company's vaccine portfolio includes preventive shots for a common respiratory infection in infants, influenza vaccines, COVID vaccines and vaccines for infections like meningitis and tetanus.

Reuters 14 hours ago

SNY
-1.56%
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for relapsing multiple sclerosis96% of participants receiving high-dose intravenous frexalimab had no new Gd+ T1 lesions and an annualized relapse rate of 0.04 after 48 weeksSanofi has initiated global phase 3 studies of frexalimab in relapsing MS and non-relapsing secondary progressive MS

GlobeNewswire 2 days ago

SNY
-1.56%
SNYNF
Sanofi: Information concerning the total number of voting rights and shares - March 2024

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,529,599,938 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regi

GlobeNewswire 6 days ago

SNY
-1.56%
SNYNF
Sanofi - AGM 30.04.2024 - Availability of Preparatory documents

COMBINED GENERAL MEETING OF APRIL 30, 2024 AVAILABILITY OF PREPARATORY DOCUMENTS The Company’s shareholders are invited to attend the Combined General Meeting to be held on Thursday April 30, 2024 at 2:30 p.m. (CET) at the Palais des Congrès – Amphithéâtre Bleu – 2, place de la Porte Maillot – 75017 Paris. The notice of meeting (avis de réunion), including the agenda and the draft resolutions as well as the terms and conditions for participating and voting in the meeting, was published on the we

GlobeNewswire 10 days ago

SNY
-1.56%
SNYNF
10 Best Weight Loss Drug Stocks to Buy Now

In this piece, we will take a look at the ten best weight loss drug stocks to buy now. If you want to skip our introduction to the rising weight loss drug industry and how it’s one of the biggest trends on the stock market right now, then you can take a look at the […]

Insider Monkey 12 days ago

LLY
-0.64%
NVO
-1.43%
VKTX
UPDATE 2-Cyclicals drive modest gains across European stocks

The continent-wide STOXX 600 index closed up 0.2%, led by a 1.7% gain in the basic resources sector as copper prices hit their highest in more than 14 months. "Recent inflation trends in Europe stand in stark contrast to what is happening in the U.S.," as per strategists at BCA Research. "This divergence in inflationary dynamics will force the ECB to be more dovish than the Fed."

Reuters 15 days ago

SNY
-1.56%
Sanofi to Settle Claims That Heartburn Drug Zantac Caused Cancer

The French healthcare company said the deal would require the consent of individual plaintiffs and would take time to conclude.

The Wall Street Journal 15 days ago

SNY
-1.56%
SNYNF
UPDATE 2-Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday. Sanofi did not disclose the financial terms of the deal. The agreement, which still needs to be finalized, will resolve most of the lawsuits against the French pharmaceutical company in U.S. state courts, with the exception of Delaware where the majority of the cases are pending.

Reuters 15 days ago

SNY
-1.56%
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 21 days ago

DNLI

SNY
-1.56%
HALO
32 Countries with the Highest Rates of Diabetes

In this article, we will be taking a look at the 32 countries with the highest rates of diabetes. If you do not want to learn about the global diabetes market, head straight to the 5 Countries with the Highest Rates of Diabetes. The Global Diabetes Market and Its Implications The global diabetes market is […]

Insider Monkey 24 days ago

SNY
-1.56%
NVO
-1.43%
Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript March 21, 2024 Innate Pharma S.A. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: At this time, I would like to welcome everyone to the Innate Pharma Full Year 2023 Financial […]

Insider Monkey 27 days ago

SNY
-1.56%
IPH.PA

AZN
-0.25%
Press Release: Availability of the Q1 2024 Memorandum for modelling purposes

Availability of the Q1 2024 Memorandum for modelling purposes Paris, France – March 22, 2024. Sanofi announced today that its Q1 2024 Memorandum for modelling purposes is available on the "Investors" page of the company's website: First quarter 2024 results (sanofi.com) As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the for

GlobeNewswire 28 days ago

SNY
-1.56%
SNYNF
Mirador Therapeutics raises over $400 mln in early funding rounds

Mirador Therapeutics said on Thursday it had secured more than $400 million to develop precision medicines for immune-related diseases, in a rare, large early-stage fundraise. Easing inflationary pressures, increasing bets of a soft landing and promising data from drug trials are starting to boost the biotech funding market, which saw a downturn last year along with other industries. "This is one of the largest series A rounds, probably in history, certainly this year," Mirador CEO and founder Mark McKenna said, without disclosing the valuation at which the funds were raised or the breakdown of the amounts raised in the latest two rounds.

Reuters 28 days ago

SNY
-1.56%
Sanofi: Information concerning the total number of voting rights and shares - February 2024

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,529,599,938 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regi

GlobeNewswire last month

SNY
-1.56%
SNYNF
12 Most Profitable Biotech Stocks To Invest In

In this piece, we will take a look at the 12 most profitable biotech stocks to invest in. If you want to skip our overview of the global biotechnology industry and the latest trends, then you can take a look at the 5 Most Profitable Biotech Stocks To Invest In. Biotechnology is the riskiest and […]

Insider Monkey last month

NVO
-1.43%
AZN
-0.25%
ABBV
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study

ASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with eczema, who have previously been treated with Dupixent but did not achieve an adequate response.

Zacks last month

SNY
-1.56%
ASLN

REGN
-0.80%
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis

New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis Late-breaking data at AAD show sustained off-drug improvements of AD signs and symptoms with amlitelimab for 28 weeks The safety profile for patients dosed to 52 weeks was consistent with amlitelimab 24 weeks data showing it to be well-tolerated with no new safety concerns identifiedDurability of response supports quarterly dosing currently being investigated in Phase 3 pivotal p

GlobeNewswire last month

SNY
-1.56%
SNYNF
UPDATE 2-Astra-Sanofi's RSV therapy 90% effective against infant hospitalizations, CDC study shows

AstraZeneca and Sanofi's antibody therapy was 90% effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV), a U.S. CDC study showed. Although the data available for analysis is limited, CDC said the early estimates support the current recommendation of use in infants. In August, the CDC had recommended the use of the therapy in infants below eight months of age born during or entering their first RSV season, as well as in children aged 8-19 months who remain vulnerable to severe RSV disease through their second season.

Reuters last month

AZN
-0.25%
SNY
-1.56%
13 Best Pharma Dividend Stocks To Buy in 2024

In this article, we discuss 13 best pharma dividend stocks to buy in 2024. You can skip our detailed analysis of the pharma sector and its performance, and go directly to read 5 Best Pharma Dividend Stocks To Buy in 2024. Within the healthcare industry in the US, the pharmaceutical sector has experienced significant transformations […]

Insider Monkey last month

VTRS

ZTS

SNY
-1.56%
Pharma Stock Roundup: FDA Priority Tag to SNY, ABBV Filings, CHMP Nod for AZN, JNJ, MRK

The FDA grants priority review status to Sanofi's (SNY) and AbbVie's (ABBV) sBLAs for Dupixent and Epkinly, respectively

Zacks last month

ABBV

AZN
-0.25%
SNY
-1.56%

Performance Overview

Return	SNY	CAC 40
YTD	-8.73%	+6.01%
1-Year	-14.68%	+6.14%
3-Year	-0.98%	+27.19%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sanofi (SNY)

Sanofi to overhaul US operations of vaccines, cut jobs

Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

Sanofi: Information concerning the total number of voting rights and shares - March 2024

Sanofi - AGM 30.04.2024 - Availability of Preparatory documents

10 Best Weight Loss Drug Stocks to Buy Now

UPDATE 2-Cyclicals drive modest gains across European stocks

Sanofi to Settle Claims That Heartburn Drug Zantac Caused Cancer

UPDATE 2-Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?

32 Countries with the Highest Rates of Diabetes

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript

Press Release: Availability of the Q1 2024 Memorandum for modelling purposes

Mirador Therapeutics raises over $400 mln in early funding rounds

Sanofi: Information concerning the total number of voting rights and shares - February 2024

12 Most Profitable Biotech Stocks To Invest In

ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study

Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis

UPDATE 2-Astra-Sanofi's RSV therapy 90% effective against infant hospitalizations, CDC study shows

13 Best Pharma Dividend Stocks To Buy in 2024

Pharma Stock Roundup: FDA Priority Tag to SNY, ABBV Filings, CHMP Nod for AZN, JNJ, MRK

Performance Overview